Well then Tasly and Mesoblast can choose to expand the license agreement or another, probably Chinese company can take up a license agreement for remestemcel-L.
Tasly makes much more sense though especially as they already know about Mesoblast manufacturing, have the expertise to do it and have a massive reach across hospitals in China. This is a slide summarising IP from the recent, 2020 Global Biotech Showcase.
All depends if by a standardised MSC product they will accept one made by a local business, with royalties flowing off shore.
- Forums
- ASX - By Stock
- MSB
- Mesoblast owns the patents . The science is now proven .
Mesoblast owns the patents . The science is now proven ., page-18
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 94863 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 5000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85863 | 1.125 |
8 | 142044 | 1.120 |
8 | 196927 | 1.115 |
16 | 394801 | 1.110 |
4 | 48412 | 1.105 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 5000 | 2 |
1.135 | 15000 | 2 |
1.140 | 37912 | 2 |
1.145 | 27912 | 2 |
1.150 | 55804 | 4 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |